Optic neuropathy in refractory neurosarcoidosis treated with TNF-α antagonist

Salama, Batoul; Gicquel, Jj; Lenoble, Patrice; Dighiero, P.

doi:10.3129/i06-074

Cited by 24 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there have been no comparative trials between the biologic agents for sarcoidosis, infliximab is the most heavily reported medication in the literature [6–11], and overall has shown great promise in the treatment of sarcoidosis patients refractory to more conventional therapies [6, 7, 12, 26]. Favorable outcomes of infliximab therapy in patients who have renal sarcoidosis [13], vertebral sarcoidosis [14], joint sarcoidosis [15], optic neuropathy [16], pulmonary sarcoidosis [6, 17], retinal vasculitis [18], cutaneous sarcoidosis [3–5, 22], neurosarcoidosis [19], and cardiac sarcoidosis [20] have also been reported.…”

Section: Discussionmentioning

confidence: 99%

A Case Series of Refractory Cutaneous Sarcoidosis Successfully Treated with Infliximab

Tuchinda

Bremmer

Gaspari

2012

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

IntroductionSarcoidosis is a systemic granulomatous disease of unknown cause. The management of sarcoidosis remains problematic. Systemic and topical corticosteroids are the mainstay of therapy but may cause unacceptable side effects. Biologic therapies, such as infliximab, have recently been proposed as another treatment option for cutaneous sarcoidosis.Case ReportThe authors describe three patients who were diagnosed with cutaneous sarcoidosis with systemic involvement. All of the patients were refractory to conventional therapies but responded to infliximab therapy.ConclusionInfliximab is an alternative medication for refractory sarcoidosis that has a relatively benign side-effect profile. However, definite indications, dosage, interval, and duration of treatment for cutaneous sarcoidosis are not firmly established.

show abstract